Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic, Gastric Cancer
Conditions
Keywords
gastrointestinal cancer
Brief summary
The primary objective of the phase 1 portion of this study is to determine the recommended dose of bemarituzumab in combination with 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) to use in the phase 2 portion of the trial.
Detailed description
Phase 1 is an open-label dose-escalation of bemarituzumab in combination with modified FOLFOX6 (mFOLFOX6). Eligible patients will have unresectable locally advanced or metastatic GI cancer of any type and be candidates to receive at least 2 doses of mFOLFOX6 chemotherapy. Phase 1 consists of 2 dosing cohorts of bemarituzumab in combination with mFOLFOX6 to determine the recommended dose of bemarituzumab in combination with mFOLFOX6 for the phase 2 portion of the study (see study record NCT03694522).
Interventions
BIOLOGICALBemarituzumab
Administered by intravenous infusion over approximately 30 minutes
DRUGModified FOLFOX6
Modified FOLFOX6 regimen consists of the following: * Oxaliplatin 85 mg/m² IV infusion over 120 minutes * Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable * 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours.
Sponsors
Five Prime Therapeutics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Disease that is unresectable, locally advanced, or metastatic (not amendable to curative therapy) 2. Understand and sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent form (ICF) prior to any study-specific evaluation 3. Life expectancy of at least 3 months in the opinion of the investigator 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 5. Age ≥ 18 years at the time the ICF is signed 6. In sexually active patients (women of childbearing potential and males), willingness to use 2 effective methods of contraception, of which 1 must be a physical barrier method (condom, diaphragm, or cervical/vault cap) until 6 months after the last dose of FPA144. Other effective forms of contraception include: * Permanent sterilization (hysterectomy and/or bilateral oophorectomy, or bilateral tubal ligation with surgery, or vasectomy) at least 6 months prior to Screening * Women of childbearing potential who are on stable oral contraceptive therapy or intrauterine or implant device for at least 90 days prior to the study, or abstain from sexual intercourse as a way of living 7. Adequate hematological and biological function, confirmed by the following laboratory values within 96 hours prior to enrollment: Bone Marrow Function * Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L * Platelets ≥ 100 × 10\^9/L * Hemoglobin ≥ 9 g/dL Hepatic Function * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 × upper limit of normal (ULN); if liver metastases, then \< 5 × ULN * Bilirubin \< 1.5 × ULN except in patients with Gilbert's disease Renal Function * Calculated creatinine clearance using cockcroft Gault formula ≥ 50 mL/min or estimated glomerular filtrate rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula ≥ 50 mL/min 8. International normalized ratio (INR) or prothrombin time (PT) \< 1.5 x the ULN except for patients receiving anticoagulation, who must be on a stable dose of warfarin for 6 weeks prior to enrollment 9. Measurable or non-measurable, but evaluable disease using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 10. Histologically or cytologically confirmed GI malignancy for which mFOLFOX6 is considered an appropriate treatment (e.g., gastric cancer \[GC\], colorectal carcinoma, pancreatic adenocarcinoma) 11. Patient must be a candidate to receive at least 2 doses of mFOLFOX6 chemotherapy
Exclusion criteria
1. Untreated or symptomatic central nervous system (CNS) metastases (CNS imaging not required). Patients with asymptomatic CNS metastases are eligible provided they have been clinically stable for at least 4 weeks and do not require intervention such as surgery, radiation, or any corticosteroid therapy for management of symptoms related to CNS disease 2. Impaired cardiac function or clinically significant cardiac disease, including any of the following (Criteria a through g): 1. Unstable angina pectoris ≤ 6 months prior to enrollment 2. Acute myocardial infarction ≤ 6 months prior to enrollment 3. New York Heart Association Class II-IV congestive heart failure 4. Uncontrolled hypertension (as defined as ≥ 160/90 despite optimal medical management) 5. Uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin 6. Active coronary artery disease 7. Fridericia's corrected QT interval (QTcF) ≥ 480 3. Peripheral sensory neuropathy ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 4. Active infection requiring systemic treatment or any uncontrolled infection ≤ 14 days prior to enrollment 5. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known active or chronic hepatitis B or C infection 6. History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) 7. Evidence or history of bleeding diathesis or coagulopathy 8. Radiotherapy ≤ 28 days of enrollment. Patients must be recovered from all acute radiotherapy-related toxicities. No radiopharmaceuticals (strontium, samarium) within 8 weeks of enrollment 9. Prior treatment with any selective inhibitor (e.g., AZD4547, BGJ398, JNJ-42756493, BAY1179470) of the fibroblast growth factor (FGF)-FGFR pathway 10. Ongoing adverse effects from prior systemic treatment \> CTCAE Grade 1 (with the exception of Grade 2 alopecia) 11. Participation in another therapeutic clinical study or receiving any investigational agent within 28 days of enrollment or during this clinical study 12. Corneal defects, corneal ulcerations, keratitis, keratoconus, history of corneal transplant, or other known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer 13. Known positivity for human epidermal growth factor receptor 2 (HER2) (as defined by a positive immunohistochemistry \[IHC\] test of 3+ or IHC of 2+ with fluorescent in situ hybridization \[FISH\]) 14. Major surgical procedures not permitted ≤ 28 days prior to enrollment. Surgery requiring local/epidural anesthesia must be completed at least 72 hours before enrollment. In all cases the patient must be sufficiently recovered and stable before treatment administration 15. Women who are pregnant or breastfeeding (unless the patient is willing to interrupt breastfeeding during study treatment administration and then resume 6 months after study discontinuation); women of childbearing potential must not consider getting pregnant during the study 16. Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study (e.g., substance abuse, psychiatric disturbance, uncontrolled intercurrent illness including arterial thrombosis, or symptomatic pulmonary embolism) 17. Presence of any other condition that may increase the risk associated with study participation, or may interfere with the interpretation of study results, and, in the opinion of the investigator, would make the patient inappropriate for entry in the study 18. Known allergy, hypersensitivity or contraindication to components of the FPA144 formulation including polysorbate or to platinum-containing medications, 5-FU, or leucovorin 19. History of prior malignancy, except (Criteria a through f): 1. Curatively treated non-melanoma skin malignancy 2. Cervical cancer in situ 3. Curatively treated Stage I uterine cancer 4. Curatively treated ductal or lobular breast carcinoma in situ and not currently receiving any systemic therapy 5. Localized prostate cancer that has been treated surgically with curative intent and presumed cured 6. Solid tumor treated curatively more than 5 years previously without evidence of recurrence
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment-related Adverse Events ≥ Grade 2 | From first dose of study drug up to 28 days after last dose; Actual median (min, max) duration of treatment emergent period was 19.3 (12.3, 22.3) weeks in the bemarituzumab 6 mg/kg group and 19.4 (4.0, 35.4) weeks in the bemarituzumab 15 mg/kg group. | A treatment-related adverse event (TRAE) is defined as an adverse event (AE) with an onset date on or after the date of first dose of study treatment, or an event present before treatment that worsened after treatment, and with an onset date prior to 28 days after the last date of dose, for which the investigator assessed as related to investigational product The investigator classified the severity of each AE using the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0 on a scale from mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), or death due to the AE (Grade 5). |
| Number of Participants With Dose Limiting Toxicities (DLTs) | 28 days | DLTs were defined as any of the following events considered by the investigator to be related to study drug: * Absolute neutrophil count (ANC) \< 0.5 × 10⁹/L \> 5 days duration or febrile neutropenia. * Platelets \< 25 × 10⁹/L or \< 50 × 10⁹/L with bleeding requiring medical intervention or for \> 3 days. * Grade 4 anemia. * Any Grade 2-3 ophthalmologic AE not resolving within 7 days. * Any Grade 4 ophthalmologic AE. * Any Grade 4 laboratory value. * Any Grade 3 laboratory values that are not of clinical significance according to investigator and Sponsor agreement if they do not resolve within 72 hours. * Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≥ 3× upper limit of normal (ULN) and concurrent total bilirubin ≥ 2× ULN not related to liver involvement with cancer. * Any non-hematological AE ≥ Grade 3 (except nausea, vomiting, and diarrhea). * Grade 3 nausea, vomiting or diarrhea not resolving with supportive care in 72 hours. * Grade 4 nausea, vomiting or diarrhea. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Observed Serum Concentration of Bemarituzumab at the End of the Dose Interval (Ctrough) | Cycle 1 day 14 predose for cohort 1 and day 8 predose for cohort 2; Cycle 2 day 14 predose | — |
| Area Under the Observed Concentration-time Curve From the Time of Dosing to Day 14 (AUC0-14) | Cycle 1 day 1 at predose, 0.25, 4, 48, and 168 hours after end of infusion, and for participants in Cohort 2 day 8 at 0.25 and 4 hours after the end of infusion. | Area under the observed concentration-time curve from the time of dosing to Day 14 (0-336h) calculated by log-linear trapezoidal approximation. |
| Number of Participants With Treatment-emergent Adverse Events | From first dose of study drug up to 28 days after last dose; Actual median (min, max) duration of the treatment emergent period was 19.3 (12.3, 22.3) weeks in the bemarituzumab 6 mg/kg group and 19.4 (4.0, 35.4) weeks in the bemarituzumab 15 mg/kg group. | Treatment-emergent adverse events are defined as adverse events (AEs) that started or worsened between the start of study drug and 28 days after permanent discontinuation of study drug. A serious AE is defined as any untoward medical occurrence that at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability or incapacity; * Was a congenital anomaly or birth defect. The investigator assessed the causality/relationship between the study treatment and each AE, and assessed the severity of each AE according to the guidelines provided in NCI-CTCAE, version 5.0 on a scale from mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), or death due to the AE (Grade 5). Ocular events associated with symptomatic corneal involvement and symptomatic and asymptomatic retinal involvement were events of special interest in this study. |
| Number of Participants With Treatment Induced Anti-bemarituzumab Antibodies | Samples were collected for ADA analysis predose on day 1 of Cycles 1, 2, 3, 7, and 10 and at 28 days following the last dose. | Postbaseline treatment induced antidrug antibody (ADA) positive is defined as participants with * ADA negative at baseline and ADA positive at any postbaseline timepoint, or * ADA positive at baseline and ADA positive with titer of at least 4-fold of the baseline titer at one or more postbaseline timepoint. |
| Terminal Half-life (t1/2) of Bemarituzumab | Cycle 1 day 1 at predose, 0.25, 4, 48, and 168 hours after end of infusion, and for participants in Cohort 2 day 8 at 0.25 and 4 hours after end of infusion. | — |
| Maximum Observed Serum Concentration (Cmax) of Bemarituzumab | Cycle 1 day 1 at predose, 0.25, 4, 48, and 168 hours after end of infusion, and for participants in Cohort 2 day 8 at 0.25 and 4 hours end of infusion; Cycle 2 day 1 at predose, 0.25 and 48 hours after end of infusion. | — |
Countries
United States
Participant flow
Recruitment details
Study FPA144-004 was a Phase 1/2 study. Phase 1 was a safety run-in to determine the recommended dose of bemarituzumab to be administered in combination with a fixed dose of modified FOLFOX 6 (mFOLFOX6) chemotherapy regimen in the phase 2 part of the study. Phase 1 study results are reported herein; Phase 2 study details and results are reported separately (NCT03694522).
Pre-assignment details
In Phase 1, dose cohorts were planned to begin at a bemarituzumab dose level of 6 mg/kg per dose, with enrollment into subsequent dose cohorts depending on safety and tolerability.
Participants by arm
| Arm | Count |
|---|---|
| Bemarituzumab 6 mg/kg + mFOLFOX6 Participants received 6 mg/kg bemarituzumab administered Q2W and mFOLFOX6 chemotherapy administered Q2W until unacceptable toxicity, disease progression, or death. | 3 |
| Bemarituzumab 15 mg/kg + mFOLFOX6 Participants received 15 mg/kg bemarituzumab administered Q2W with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death. | 9 |
| Total | 12 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 0 | 2 |
| Overall Study | Missing | 2 | 0 |
| Overall Study | Other | 0 | 6 |
| Overall Study | Withdrawal by Subject | 1 | 1 |
Baseline characteristics
| Characteristic | Bemarituzumab 6 mg/kg + mFOLFOX6 | Bemarituzumab 15 mg/kg + mFOLFOX6 | Total |
|---|---|---|---|
| Age, Continuous | 64.7 years STANDARD_DEVIATION 21.46 | 62.3 years STANDARD_DEVIATION 16.45 | 62.9 years STANDARD_DEVIATION 16.78 |
| Age, Customized < 65 years | 1 Participants | 5 Participants | 6 Participants |
| Age, Customized >=65 years | 2 Participants | 4 Participants | 6 Participants |
| Anti-Cancer Treatment Prior to Enrollment No | 1 Participants | 2 Participants | 3 Participants |
| Anti-Cancer Treatment Prior to Enrollment Yes | 2 Participants | 7 Participants | 9 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 0 (Fully active) | 0 Participants | 6 Participants | 6 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 1 (Restricted activity but ambulatory) | 3 Participants | 3 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 2 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants | 7 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Black or African American | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Other | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized White | 2 Participants | 7 Participants | 9 Participants |
| Sex: Female, Male Female | 2 Participants | 0 Participants | 2 Participants |
| Sex: Female, Male Male | 1 Participants | 9 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 2 / 9 |
| other Total, other adverse events | 3 / 3 | 9 / 9 |
| serious Total, serious adverse events | 0 / 3 | 4 / 9 |
Outcome results
Primary
Number of Participants With Dose Limiting Toxicities (DLTs)
DLTs were defined as any of the following events considered by the investigator to be related to study drug: * Absolute neutrophil count (ANC) \< 0.5 × 10⁹/L \> 5 days duration or febrile neutropenia. * Platelets \< 25 × 10⁹/L or \< 50 × 10⁹/L with bleeding requiring medical intervention or for \> 3 days. * Grade 4 anemia. * Any Grade 2-3 ophthalmologic AE not resolving within 7 days. * Any Grade 4 ophthalmologic AE. * Any Grade 4 laboratory value. * Any Grade 3 laboratory values that are not of clinical significance according to investigator and Sponsor agreement if they do not resolve within 72 hours. * Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≥ 3× upper limit of normal (ULN) and concurrent total bilirubin ≥ 2× ULN not related to liver involvement with cancer. * Any non-hematological AE ≥ Grade 3 (except nausea, vomiting, and diarrhea). * Grade 3 nausea, vomiting or diarrhea not resolving with supportive care in 72 hours. * Grade 4 nausea, vomiting or diarrhea.
Time frame: 28 days
Population: DLT-evaluable population includes all participants enrolled in Phase 1 of the study who received at least 2 doses of bemarituzumab (except for Cohort 2 \[must have received 3 doses of bemarituzumab\]) and mFOLFOX6 and completed Cycles 1 and 2 of treatment, or who experienced a DLT in Cycle 1 or Cycle 2.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Dose Limiting Toxicities (DLTs) | 0 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Dose Limiting Toxicities (DLTs) | 0 Participants |
Primary
Number of Participants With Treatment-related Adverse Events ≥ Grade 2
A treatment-related adverse event (TRAE) is defined as an adverse event (AE) with an onset date on or after the date of first dose of study treatment, or an event present before treatment that worsened after treatment, and with an onset date prior to 28 days after the last date of dose, for which the investigator assessed as related to investigational product The investigator classified the severity of each AE using the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0 on a scale from mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), or death due to the AE (Grade 5).
Time frame: From first dose of study drug up to 28 days after last dose; Actual median (min, max) duration of treatment emergent period was 19.3 (12.3, 22.3) weeks in the bemarituzumab 6 mg/kg group and 19.4 (4.0, 35.4) weeks in the bemarituzumab 15 mg/kg group.
Population: All participants who received any portion of at least 1 dose of study treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-related Adverse Events ≥ Grade 2 | 1 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-related Adverse Events ≥ Grade 2 | 4 Participants |
Secondary
Area Under the Observed Concentration-time Curve From the Time of Dosing to Day 14 (AUC0-14)
Area under the observed concentration-time curve from the time of dosing to Day 14 (0-336h) calculated by log-linear trapezoidal approximation.
Time frame: Cycle 1 day 1 at predose, 0.25, 4, 48, and 168 hours after end of infusion, and for participants in Cohort 2 day 8 at 0.25 and 4 hours after the end of infusion.
Population: Participants who received bemarituzumab with available AUC data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Area Under the Observed Concentration-time Curve From the Time of Dosing to Day 14 (AUC0-14) | 556 μg*day/mL | Standard Deviation 232 |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Area Under the Observed Concentration-time Curve From the Time of Dosing to Day 14 (AUC0-14) | 2350 μg*day/mL | Standard Deviation 394 |
Secondary
Maximum Observed Serum Concentration (Cmax) of Bemarituzumab
Time frame: Cycle 1 day 1 at predose, 0.25, 4, 48, and 168 hours after end of infusion, and for participants in Cohort 2 day 8 at 0.25 and 4 hours end of infusion; Cycle 2 day 1 at predose, 0.25 and 48 hours after end of infusion.
Population: Participants who received bemarituzumab with available Cmax data
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Maximum Observed Serum Concentration (Cmax) of Bemarituzumab | Cycle 1 | 119 µg/mL | Standard Deviation 8.52 |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Maximum Observed Serum Concentration (Cmax) of Bemarituzumab | Cycle 2 | 123 µg/mL | Standard Deviation 13.8 |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Maximum Observed Serum Concentration (Cmax) of Bemarituzumab | Cycle 1 | 329 µg/mL | Standard Deviation 60.3 |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Maximum Observed Serum Concentration (Cmax) of Bemarituzumab | Cycle 2 | 377 µg/mL | Standard Deviation 82.8 |
Secondary
Number of Participants With Treatment-emergent Adverse Events
Treatment-emergent adverse events are defined as adverse events (AEs) that started or worsened between the start of study drug and 28 days after permanent discontinuation of study drug. A serious AE is defined as any untoward medical occurrence that at any dose: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability or incapacity; * Was a congenital anomaly or birth defect. The investigator assessed the causality/relationship between the study treatment and each AE, and assessed the severity of each AE according to the guidelines provided in NCI-CTCAE, version 5.0 on a scale from mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), or death due to the AE (Grade 5). Ocular events associated with symptomatic corneal involvement and symptomatic and asymptomatic retinal involvement were events of special interest in this study.
Time frame: From first dose of study drug up to 28 days after last dose; Actual median (min, max) duration of the treatment emergent period was 19.3 (12.3, 22.3) weeks in the bemarituzumab 6 mg/kg group and 19.4 (4.0, 35.4) weeks in the bemarituzumab 15 mg/kg group.
Population: All participants who received any portion of at least 1 dose of study treatment.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE with Grade ≥ 3 | 1 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE of special interest: corneal/retina leading to discontinuation of bemarituzumab | 0 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE related to any study drug | 3 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE of special interest: corneal/retina | 0 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE related to bemarituzumab | 2 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE leading to discontinuation of bemarituzumab | 0 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE related to any agent of mFOLFOX6 | 3 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | SAE related to any agent of mFOLFOX6 | 0 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE with Grade ≥ 3 related to any study drug | 1 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE leading to discontinuation of any agent of mFOLFOX6 | 0 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | Serious adverse event (SAE) | 0 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE of special interest: corneal/retina related to bemarituzumab | 0 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | SAE related to any study drug | 0 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE leading to dose reduction of bemarituzumab | 1 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE leading to dose reduction of any agent of mFOLFOX6 | 1 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | Any treatment-emergent adverse event (TEAE) | 3 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE leading to death (Grade 5) | 0 Participants |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | SAE related to bemarituzumab | 0 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE leading to death (Grade 5) | 0 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | SAE related to bemarituzumab | 0 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | SAE related to any agent of mFOLFOX6 | 1 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE of special interest: corneal/retina | 4 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE of special interest: corneal/retina related to bemarituzumab | 4 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE of special interest: corneal/retina leading to discontinuation of bemarituzumab | 2 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE leading to discontinuation of bemarituzumab | 4 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE leading to discontinuation of any agent of mFOLFOX6 | 4 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | Any treatment-emergent adverse event (TEAE) | 9 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE with Grade ≥ 3 | 6 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE related to any study drug | 9 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE related to bemarituzumab | 5 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE related to any agent of mFOLFOX6 | 9 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE with Grade ≥ 3 related to any study drug | 4 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | Serious adverse event (SAE) | 4 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE leading to dose reduction of bemarituzumab | 0 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | TEAE leading to dose reduction of any agent of mFOLFOX6 | 5 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment-emergent Adverse Events | SAE related to any study drug | 1 Participants |
Secondary
Number of Participants With Treatment Induced Anti-bemarituzumab Antibodies
Postbaseline treatment induced antidrug antibody (ADA) positive is defined as participants with * ADA negative at baseline and ADA positive at any postbaseline timepoint, or * ADA positive at baseline and ADA positive with titer of at least 4-fold of the baseline titer at one or more postbaseline timepoint.
Time frame: Samples were collected for ADA analysis predose on day 1 of Cycles 1, 2, 3, 7, and 10 and at 28 days following the last dose.
Population: The ADA-evaluable analysis set includes all enrolled participants who received at least 1 dose of bemarituzumab and had at least 1 ADA sample drawn at any timepoint with available ADA data.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Number of Participants With Treatment Induced Anti-bemarituzumab Antibodies | 0 Participants |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Number of Participants With Treatment Induced Anti-bemarituzumab Antibodies | 0 Participants |
Secondary
Observed Serum Concentration of Bemarituzumab at the End of the Dose Interval (Ctrough)
Time frame: Cycle 1 day 14 predose for cohort 1 and day 8 predose for cohort 2; Cycle 2 day 14 predose
Population: Participants who received bemarituzumab with available Ctrough data
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Observed Serum Concentration of Bemarituzumab at the End of the Dose Interval (Ctrough) | Cycle 1 | 16.5 µg/mL | Standard Deviation 8.8 |
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Observed Serum Concentration of Bemarituzumab at the End of the Dose Interval (Ctrough) | Cycle 2 | 25.6 µg/mL | Standard Deviation 10.6 |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Observed Serum Concentration of Bemarituzumab at the End of the Dose Interval (Ctrough) | Cycle 1 | 118 µg/mL | Standard Deviation 25.1 |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Observed Serum Concentration of Bemarituzumab at the End of the Dose Interval (Ctrough) | Cycle 2 | 131 µg/mL | Standard Deviation 55.3 |
Secondary
Terminal Half-life (t1/2) of Bemarituzumab
Time frame: Cycle 1 day 1 at predose, 0.25, 4, 48, and 168 hours after end of infusion, and for participants in Cohort 2 day 8 at 0.25 and 4 hours after end of infusion.
Population: Participants who received bemarituzumab with available half-life data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Bemarituzumab 6 mg/kg + mFOLFOX6 | Terminal Half-life (t1/2) of Bemarituzumab | 8.35 days | Standard Deviation 3.36 |
| Bemarituzumab 15 mg/kg + mFOLFOX6 | Terminal Half-life (t1/2) of Bemarituzumab | 4.23 days | Standard Deviation 0.447 |